Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value-Based Care
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia
By
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—An analysis of real-world administrative claims data in patients with chronic lymphocytic leukemia (CLL) has highlighted the need for treatments that result in fewer adverse events, according to data presented at ASH 2018.
Read Article
Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?
By
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—For children and young adults diagnosed with acute lymphoblastic leukemia (ALL), receiving treatment at specialized cancer centers has been associated with improved outcomes versus nonspecialized centers, but this comes at an increased cost, according to data presented at ASH 2018.
Read Article
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
By
Chase Doyle
Economics & Value
,
Value-Based Care
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—Analysis of healthcare utilization among Medicare beneficiaries with multiple myeloma suggests that the setting of autologous hematopoietic stem-cell transplantation (HSCT) has a significant impact on provider reimbursement and out-of-pocket expenses for patients, according to data presented at ASH 2018.
Read Article
CAR T-Cell Therapy: Can We Afford the Cure?
By
Meg Barbor, MPH
Value-Based Care
,
Economics & Value
December 2018, Vol 9, No 4
Chicago, IL—So far, 2 chimeric antigen receptor (CAR) T-cell therapies have been approved by the FDA for some types of relapsed or refractory lymphoma and leukemia. Although CAR T-cell therapy has shown promise in many patients who have run out of standard treatment options, it is incredibly resource-intense: the complexities of its administration require an interdisciplinary approach for success, the side effects can be severe, and its high cost can reach upward of $1 million per course of treatment.
Read Article
Addressing Financial Toxicity Through Systematic Change
By
Meg Barbor, MPH
Value-Based Care
,
Economics & Value
December 2018, Vol 9, No 4
Although the cost of care can have severe effects on patients with cancer and their families, oncologists rarely address financial toxicity, according to Hanna K. Sanoff, MD, MPH, Medical Director, University of North Carolina (UNC) NC Cancer Hospital Clinics.
Read Article
Do No Financial Harm: How to Improve Cost Transparency in Cancer Care
Economics & Value
,
Value-Based Care
December 2018, Vol 9, No 4
Read Article
Cost of Treating Colorectal Cancer in the United States Double That of Canada, with No Survival Benefitc
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Healthcare costs in the United States have spiraled out of control, and polls show that single-payer healthcare is gaining traction.
Read Article
PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer
By
Chase Doyle
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“NGS decreased the cost of testing, identified the highest percentage of targetable genetic alterations, and had the fastest turnaround,” reported Nathan A. Pennell, MD, PhD.
Read Article
Discussing Costs with Your Patient Can Reduce Financial Toxicity
By
Chase Doyle
Economics & Value
,
Financial Toxicity
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue. You can try to prevent it, but to some degree, patients are going to experience it, and when they do, you need a plan,” says Yousuf Zafar, MD, MHS.
Read Article
Page 4 of 12
1
2
3
4
5
6
7
Top Trending Articles
1.
HOPA Highlights: What's New in 2025?
2.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma